Preterm IV Nutrition: Do Extra Amino Acids Help

Why did researchers test extra amino acids in premature babies?

On September 4, the FDA announced temporary policies intended to maintain access to starter parenteral nutrition for newborns facing potential supply gaps. These intravenous products support premature and critically ill babies who cannot receive sufficient nutrition through feeding. Their availability also brings attention to an enduring clinical question: which nutrient doses produce the best long-term outcomes? [FDA announcement](https://www.fda.gov/news-events/press-announcements/fda-takes-steps-maintain-newborn-access-life-saving-starter-nutrition-products).

The ProVIDe randomized trial enrolled 434 infants weighing less than 1,000 grams at birth. Researchers compared an additional gram of intravenous amino acids daily for five days with placebo, alongside usual nutrition in both groups. Amino acids supply the building blocks of protein; the trial tested whether increasing their early delivery improved survival without developmental disability. It therefore evaluated a supplement to established care, rather than whether babies should receive essential nutrition. [Original trial](https://pubmed.ncbi.nlm.nih.gov/36322845/).

What did the school-age follow-up find?

Published in Pediatrics in June, the follow-up assessed 280 children at 6–7 years of corrected age. The primary outcome combined survival with performance on cognitive and motor tests. There was no clear benefit from the additional amino acids. Grip strength was lower in the intervention group, while a possible disadvantage in psychosocial functioning remained uncertain. [School-age results](https://doi.org/10.1542/peds.2025-074043).

Interpretation requires care: follow-up included only the New Zealand trial centers, and some eligible children were not assessed. Secondary findings warrant confirmation. These results address a specific supplement given briefly after birth; they cannot establish that every higher-protein feeding regimen has the same effects. [Study methods and limitations](https://doi.org/10.1542/peds.2025-074043).

How should neonatal teams balance nutrition and treatment safety?

The original ProVIDe report, published in 2022, also found no improvement in survival without neurodisability at two years. A post hoc analysis identified more refeeding syndrome in the extra-amino-acid group. Because that analysis was not prespecified, it provides a safety signal rather than definitive proof of a mechanism. It reinforces the importance of studying metabolic complications alongside growth and development. [Two-year trial findings](https://pubmed.ncbi.nlm.nih.gov/36322845/).

NICE guidance recommends gradually increasing neonatal amino acid provision and supplying phosphate, with adjustments informed by blood results. It recommends daily phosphate monitoring while phosphate delivery is being increased, followed by weekly monitoring once maintenance dosing is reached, with more frequent checks when indicated. These recommendations support careful prescribing rather than automatic escalation of protein delivery. Families can ask how the team is balancing growth, blood chemistry and progress toward milk feeds. [NICE neonatal nutrition recommendations](https://www.nice.org.uk/guidance/ng154/chapter/recommendations).